MMRGlobal, Inc. has received two additional patents for its B-cell vaccine technologies. MMR has been notified it will receive another US patent protecting methods of making compositions for B-cell vaccines pursuant to a Notice of Allowance from the US Patent and Trademark Office. The patent, US Serial No.

3/293,495 entitled 'Method and Composition for Altering a B-cell Mediated Pathology,' will represent the fourth US manufacturing patent that covers the methods of making compositions for B-cell vaccines used in the fight against lymphoma and potentially other forms of cancer. Earlier this month, MMR also received a Notice of Allowance in Mexico for protecting the same technology, Mexico Serial No. MX/a/2012/009182 entitled Method and Composition for Altering a B-cell Mediated Pathology.

This will be the third issued patent in Mexico to protect this technology. Also earlier this month, MMR filed a divisional application involving similar technology in an effort to retain another pending application in Japan. The additional patent application has been filed with the Japanese Patent Office to introduce 26 additional patent claims under Patent Application No.

2013 -186384 protecting Altering a B Cell Pathology Using Self-Derived Antigens in Conjunction with Specific-Binding Cytoreductive Agent. Additional patent applications are also pending in Japan. MMR's strategy of filing continuing patent applications in countries of commercial interest like Japan allows the Company to take advantage of an international treaty to expedite receiving patents based on existing approvals in the US.

MMR has continued to make progress in protecting its biotech IP, including its anti-CD20 antibodies, and the other B-Cell vaccine patents entitled Method and Composition for Altering a B-Cell Mediated Pathology.